- Controls
- Which platforms, assays and tools the lab adopts and the technical evaluation behind them.
How to open: Ask what is slowing down the current program, such as throughput, data quality or assay development time.
Industries · Biotech
Biotech appointment setting: meetings with the scientists who pick the tools
If you sell instruments, reagents, software, bioprocess equipment or outsourced R&D to biotech companies, the person who decides is usually a scientist with a specific experiment or process problem, and the person who pays is someone else. We book meetings with the R&D and process development leaders who own those problems, timed to the funding and program milestones that open budget.
Ask Ava anything about selling biotech services
Where the pipeline comes from
The accounts a biotech program calls
- Venture-backed discovery-stage biotechs
Small teams building out labs after a funding round, choosing instruments, assay platforms and outsourced partners for the first time.
- Clinical-stage biotechs moving toward manufacturing
Programs heading into later trials need process development, scale-up, analytics and a CDMO, and the decisions get made by a few people.
- Cell and gene therapy developers
Specialized manufacturing, vector production, analytics and cold chain needs that standard suppliers often do not cover well.
- CROs and CDMOs serving biotech
Service providers buy equipment, software and consumables at volume and add capacity as they win new programs.
- Industrial and synthetic biology companies
Strain engineering, fermentation and scale-up work that needs bioreactors, screening tools and process analytics.
- University spinouts and incubator tenants
Early companies in shared lab space with grant or seed funding, often choosing their first core platforms.
Who decides
The people behind a biotech buying decision
- Controls
- Scale-up, upstream and downstream methods, and the equipment and partners used to get there.
How to open: Ask where they are in scale-up and what they plan to bring in-house versus send to a CDMO.
- Controls
- Budget, partnerships and the final call at smaller companies.
How to open: Lead with the program milestone they are trying to hit and what stands in the way, not with features.
- Controls
- Purchasing logistics, vendor setup, installation and lab space.
How to open: Use them to learn what equipment is coming and who is running the evaluation, then reach the scientist who decides.
Reasons to call
What opens a biotech account
- A new funding round
Fresh capital is spent on headcount, lab buildout and outsourced work. The weeks after an announcement are when tool and service choices get made.
- A program moving to the next stage
Going from discovery to IND-enabling work or from early to late trials changes what the company needs to buy and who it partners with.
- New lab space or a move
Buildouts mean new instruments, informatics and services chosen in a short window.
- Key hires in R&D or process development
A new head of a function often brings preferred tools and reviews existing vendors.
- A partner or CDMO falling short
Missed timelines or quality issues at an outsourcing partner push teams to look for a second source.
How it works
Your biotech outbound program
- 01
Build the list
Biotechs, service providers and research groups that fit your product, sorted by modality, program stage, funding and location, with R&D and process contacts named.
- 02
Run the outreach
A dedicated U.S.-based SDR works phone, email and LinkedIn under your company name, using accurate technical messaging that stays within your approved claims.
- 03
Book qualified meetings
Every meeting is with the right company, the right contact and a timing reason such as a funding round, a stage change or a new lab.
- 04
Nurture the rest
Companies not ready to evaluate stay in a follow-up cadence until the next milestone opens budget.
What we fix
Why biotech pipelines stall, and what changes
- Scientists ignore generic sales outreach
Your SDR learns your technology and leads with the experiment or process problem it solves, so the conversation sounds credible from the first call.
- The user and the buyer are different people
We reach the scientist who will use it and the leader who funds it, and track both in the same account notes.
- Evaluations take a long time
Follow-up stays steady through demos, data reviews and pilot runs, so deals do not stall between steps.
- Hard to know who just got funded
The list is built around funding events, program stage and hiring, so outreach reaches companies when budget is opening.
Beyond the calls
What your biotech buyers see after the first conversation
Our SDRs open the door. Our creative and inbound teams make sure what a buyer finds next, your website and the material your reps send, closes the gap.
Sales collateral Sell sheets, case studies and decks for heads of r&d or principal scientist The one-pager in the follow-up email, the case study they forward upstairs, the deck for the first meeting. See the collateral portfolio →
Websites and inbound A website that turns biotech searches into calls Pipeline Inbound builds the site, content and search presence that turn interest into conversations your team can work. Shown: Ironwatch Security. See Pipeline Inbound →
Pricing
Flat monthly programs, guaranteed in writing
Best for $2M to $10M revenue. A dedicated U.S.-based SDR at 50% capacity, a custom 1,500-account target list, phone, email and LinkedIn.
Best for $10M to $50M. A dedicated SDR at 100%, plus direct mail, intent and trigger data, and nurture up to 18 months.
Best for $50M+. A team of 2 to 6 specialists across territories and divisions.
Guaranteed. The activity or qualified-appointment number is agreed in writing before launch. If we miss it, we keep working at no additional cost until we hit it.
Exclusive. One biotech program per market: we will not run the same program for your direct competitor in your territory.
See everything each plan includes or compare with hiring an SDR.
Questions
Biotech appointment setting, answered
What kinds of companies does this fit?
Companies selling instruments, reagents and consumables, lab software and informatics, bioprocess and automation equipment, and outsourced R&D or manufacturing services to biotech companies.
How is this different from your life science program?
This program targets the scientists and process teams at biotech companies who choose research tools and partners. Our life science program targets lab operations, quality and facility buyers across pharma, medical devices and clinical labs.
How do you speak to technical audiences without overselling?
Your SDR is trained on your technology and approved claims, and leads with the scientific problem you solve. No claims go out that your team has not signed off.
Will you work for a competing company?
No. We run one program per product category in each market, so a direct competitor will not get the same accounts or messaging.
What does a program cost?
Foundation is $5,000 a month and Growth is $8,500 a month, with Enterprise quoted to scope. The activity or appointment number is guaranteed in writing, and we keep working at no extra cost until we hit it.
Getting Ava ready…
AI video guide. Your voice is processed by Tavus to run this conversation; we never use your camera. Calls end after 5 minutes. Privacy